Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > REGULATORY
REGULATORY
- Cancer Meds from Servier, Taiho, Pfizer’s AA Drug Up for Panel Review on May 29
May 16, 2023
- MHLW Issues ICH E19-Based Guideline on Selective Approach to Safety Data Collection in Clinical Trials
May 16, 2023
- 68.3% of Public Comments Supported Mefeego Approval: MHLW
May 16, 2023
- G7 Health Chiefs Vow to Spur Antibiotic and Dementia Drug Development, Access to Vaccines
May 15, 2023
- Gene Therapy Luxturna Up for MHLW Panel Review on May 26
May 15, 2023
- Komeito Lawmakers Propose Review of Off-Year Re-Pricing, Correction of Multi-Product Small-Lot Generic Production
May 12, 2023
- MOF Continues to See Macroeconomic Indexing Reasonable: Panel Meeting
May 12, 2023
- LDP Pharma Study Group Eyes Removal of Budget Cap on Social Security Spending
May 11, 2023
- Nonpartisan Lawmaker League OKs Dementia Bill, Eyes Enactment in Current Diet
May 11, 2023
- No Additional Safety Measures Needed at this Time for Xocova: Panel
May 11, 2023
- Label Revisions Ordered for 32 Hypertension Meds to Caution against Fetal Risks
May 10, 2023
- LDP’s Life Science League Submits Proposal; Ex-Minister Urges Price Debate from Industrial Policy Perspective
May 10, 2023
- MHLW Panel OKs 197 More Health Damage Claims for COVID Vaccines
May 10, 2023
- Chuikyo to Go Back Offline from May, but Online Viewing Still Available
May 9, 2023
- FY2023 COVID Booster Program Begins for Elderly, Health Workers
May 9, 2023
- Japan Shoots for 80% Replacement Rate in 60% of All Biosimilar APIs by FY2029
May 8, 2023
- PMDA, NHO Ink Database Deal, Data on 9 Million-Plus People to Be Available
May 8, 2023
- MHLW to Decide on Policy for Real-Time Supply Info System within FY2023: Official
May 8, 2023
- Japan Ends Priority Review for COVID Products with Severity Downgrade
May 8, 2023
- Ferring Japan Faces Biz Improvement Order for GMP Violation at Overseas Site
May 1, 2023
ページ
The launch of Elevidys has opened the door to gene therapy for DMD, but research into new treatments is already…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…